Editorial Staff

Drug Rebates: How Pharmacy Benefit Managers Manipulate Price & Limit Choice

/0 Comments/in , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Join host Joe Selvaggi and his guest Dr. Bill Smith as they discuss the complex incentive structure between drug manufacturers, health plans, and pharmacy benefit managers. In this episode, they focus on how drug rebates work and how a system intended to optimize value may actually deliver higher costs and fewer choices. Joe and Bill also use this framework to speculate on the price of a COVID-19 vaccine, and who will likely pay for it.

Guest:

Dr. William Smith is Visiting Fellow in Life Sciences at Pioneer Institute. Bill has recently published a working paper entitled, Growing Drug Rebates Hurt Both Consumers and our Healthcare System.  He is here to share with us his findings on how drug rebates work and how they affect which drugs we are prescribed and how much we pay. Bill has spent ten years at Pfizer as Vice President of Public Affairs and Policy, has been President of a medical device company,  and has had senior staff positions with U.S. Congressional House leadership, the White House, and in the Governor’s office in Massachusetts. He earned his PhD at the Catholic University of America and a bachelor’s degree from Georgetown University.

Get new episodes of Hubwonk in your inbox!

Related Content

Harvard’s Sullied Halo: Journalists Teach Lesson on Plagiarism

Joe Selvaggi talks with investigative reporter Chris Brunet about his role investigating and exposing former Harvard President Claudine Gay’s academic plagiarism, a story that lead to her eventual resignation.

Drug Discount Distortions: How Middlemen Increase Costs and Reduce Access

Joe Selvaggi talks with Drs. Bill Smith and Robert Popovian about how the complex system of rebates from drug companies to insurance firms serve to increase costs and reduce access for patients.

Boston’s Building Bargain: Coaxing Commercial Conversions to Condos

Joe Selvaggi discusses the strategic goals of Boston's Downtown Office to Residential Conversion Pilot Program with Arthur Jemison, the head of BPDA planning. The aim is to transform underutilized offices in Downtown into vibrant places to live.

SCOTUS Wealth Tax: Are Appreciated Assets Income?

Joe Selvaggi talks with CATO Institute constitutional scholar Thomas Berry about the recently argued Moore v. U.S.A. case, which challenges the idea that income must be realized before it can be taxed.

Busting Big Business: Antitrust Comes for Google and Big Sandwich

Joe Selvaggi talks with Dr. Brian Albrecht, an economists with the International Center for Law and Economics. They separate fact from fiction when it comes to the public’s and politicians’ concerns over allegedly anti-consumer practices of big business and discuss when antitrust action by the federal government is justified.

Supreme Oral Arguments: Do Gun Rights Rest on Responsible Behavior

Joe Selvaggi engages in a conversation with constitutional scholar Attorney Clark Neily to explore the oral arguments presented in the US Supreme Court case USA v Rahimi. The discussion delves into the intricate examination of behavioral history and the legal processes involved in restricting an individual from owning a firearm.

Powering Earth’s Unplugged: Overcoming Barriers to Electricity Benefits Billions

Joe Selvaggi talks with energy journalist Robert Bryce about his views on the benefits and barriers to bringing cheap, abundant electricity to the nearly 4 billion people without access.

Peace Through Compassion

In a conversation between Joe Selvaggi and George Mason law professor Ilya Somin, Somin presents his viewpoint on the moral and strategic case for allowing free emigration of Palestinian refugees from the conflict zone to bolster Israel’s fight against Hamas terrorism.

Inflationary Debt Spiral: Fiscal Cliff Getting Closer, Faster

Joe Selvaggi discusses the consequences of record structural deficits and debt with budget expert Brian Riedl, a senior fellow at the Manhattan Institute. They delve into how these factors could impact the financial stability of Medicare and Social Security and examine the limited time available to avert a potential crisis.

Identity Politics Ideology: Woke’s Orthodoxy and Opposition to Liberal Values

Joe Selvaggi hosts a conversation with Johns Hopkins University Professor Yasha Mounk regarding "The Identity Trap," Mounk's latest book that delves into the origins of woke identity politics, its potential impact on classical liberal values, and strategies for its informed opponents to effectively counter its influence.

Federal Firearm Forfeiture: SCOTUS Considers Gun Rights and Due Process

Joe Selvaggi hosts a conversation with constitutional legal expert Clark Neily, who delves into the facts and legal complexities surrounding USA v. Rahimi, currently before the Supreme Court. This case questions the forfeiture of Second Amendment rights for individuals accused of domestic abuse.

Diversity’s Dubious Definition: Harvard Case Spells End to Racial Classifications

Joe Selvaggi discusses the implications of the Students for Fair Admissions v. Harvard case for race and ethnicity-based programs with David Bernstein, a Distinguished Law Professor at George Mason University and an Adjunct Fellow at the CATO Institute.

Untangling Unsheltered Encampments: Home Is Where the Help Lies

Joe Selvaggi discusses the challenges posed by homeless encampments, like Boston's Mass and Cass, with Dr. Judge Glock, the director of research at the Manhattan Institute. They also explore policy alternatives aimed at addressing the needs of both the community and the unsheltered individuals.

Ruining Research Rewards: Price Controls Come for University Patents and Products

Joe Selvaggi talks with Pioneer Institute Senior Fellow Dr. Bill Smith about the benefit of the Bayh-Dole Act’s protection of intellectual property rights for university research patents and the risk posed to the nation and the local economy from recent efforts to consider price controls on products developed from patented discoveries.